TABLE 1.

Evidence identity, scope, and eligibility of the cardiovascular synthesis.

Evidence category	Number	Role in synthesis	Representative references
Primary MIRI/reperfusion-associated myocardial injury	30	Direct evidence for reperfusion-stage redox-responsive or redox-modulating cardiovascular therapy	(Ai et al., 2021; Altshuler et al., 2021; Cheng et al., 2019; Hu et al., 2026; Ikeda et al., 2016; Liu et al., 2016; Ma et al., 2025b; Wang et al., 2025c; Wang et al., 2024c; Zhen et al., 2025)
Primary MI/post-infarction evidence	44	Direct evidence for acute MI, infarct repair, angiogenesis, fibrosis, and remodeling	(Cao et al., 2026; Ding et al., 2022; Ding et al., 2020; Ji et al., 2023; Pan et al., 2025; Song L. et al., 2025; Wang et al., 2025b; Wang et al., 2022; Wu et al., 2025a; Yang et al., 2025a)
Secondary cardiac evidence	4	Mechanistic cardiac evidence from non-coronary oxidative injury models	(Bei et al., 2020; Boarescu et al., 2019; Liu et al., 2026b; Zhao et al., 2026)
Exclusively non-cardiac evidence	22	Cross-organ material, mechanistic, imaging, or safety context only	(Afshar et al., 2024; Deng et al., 2026; Embaby et al., 2026; Feng et al., 2022; Hu et al., 2025; Ma et al., 2025a; Sheng et al., 2025; You et al., 2024; Zhang et al., 2026; Zhou et al., 2025)
Human evidence	0	No human observational or clinical-trial evidence identified	None